Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out
Executive Summary
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.
You may also be interested in...
Biogen’s Singhal Offers A Look Into Company's Pipeline Review
Priya Singhal, head of development, spoke with Scrip about the company’s R&D restructuring, readouts coming from the culled pipeline and how Biogen is thinking about adding to it in the future.
Sun Backs India-First Stroke Drug From Pharmazz
Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial. The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.
Biogen’s Latest Leadership Change Hints At Immunology Ambitions
New head of research Jane Grogan comes to Biogen from start-ups Graphite Bio and ArsenalBio, and previously held leadership positions in autoimmune and oncology R&D at Genentech.